NewCardio, a cardiac diagnostic technology provider has received notice of allowance for US patent 7647093 on January 12, 2010, titled, ‘Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing,’ from the US Patent and Trademark Office.

The company claims that this represents the core patent for CardioBip and, in conjunction with the two encouraging validation studies announced on January 5, 2010, validates the CardioBip technology, positioning NewCardio as an emerging leader in remote cardiac monitoring.

The CardioBip is a hand-held device that provides a solution for ECG telemonitoring. Patients can carry the CardioBip with them and use it to generate and transmit synthesized, accurate 12-lead ECGs at physician prescribed intervals of time, during ordinary daily activity or when symptoms develop.

CardioBip is easy to use, combined with the ability to generate recordings substantially equivalent in quality with standard 12-lead ECGs. The CardioBip works without any cables, cumbersome leads, wires or inconvenient skin electrodes, as the device’s electrodes are integrated, offering potential compatibility with hand-held PDA platforms, said the company.

Branislav Vajdic, chief executive officer of NewCardio, said: “This patent strengthens our intellectual property protection creating a significant barrier to entry for a competing device. We believe the CardioBip technology fills an important technological and diagnostic void, enabling not only rhythm diagnosis, but also detection of ischemic ECG changes and precise reconstruction of atrial activity.”